Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PRO-143 Ophthalmic Solution in Healthy Volunteers
NCT03698045Phase 1Withdrawn
- Sponsor
- Laboratorios Sophia
- Start
- Nov 2013
- Primary completion
- Feb 2014
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRO-143 in bacterial conjunctivitis (BC), sponsored by Laboratorios Sophia. Primary endpoints: Conjunctival bulbar hyperemia at 10 days and Number of Participants with adverse events at 10 days. Planned start Nov 2013; status: withdrawn.
02
Drugs
PRO-143
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT03698045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698045.